U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N
Molecular Weight 135.2062
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROAMPHETAMINE

SMILES

C[C@H](N)CC1=CC=CC=C1

InChI

InChIKey=KWTSXDURSIMDCE-QMMMGPOBSA-N
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

HIDE SMILES / InChI

Molecular Formula C9H13N
Molecular Weight 135.2062
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf | https://www.drugs.com/ppa/lisdexamfetamine.html | https://www.ncbi.nlm.nih.gov/pubmed/27125257

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

2007
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

2007
Primary
DEXEDRINE

Approved Use

Narcolepsy. Attention Deficit Disorder with Hyperactivity. As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

Launch Date

1980
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.9 ng/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
24.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
36.6 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
60.7 ng × h/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
431 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.1 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Disc. AE: Irritability, Decreased appetite...
AEs leading to
discontinuation/dose reduction:
Irritability (1.3%)
Decreased appetite (0.86%)
Insomnia (0.86%)
Sources:
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Disc. AE: Delirium, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Delirium (acute)
Tachycardia
Hypertension
Tachypnea
Creatine kinase increased (mild)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Disc. AE: Insomnia, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Insomnia (2%)
Tachycardia (1%)
Irritability (1%)
Hypertension (1%)
Headache (1%)
Anxiety (1%)
Dyspnea (1%)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Disc. AE: Ventricular hypertrophy, Tic...
AEs leading to
discontinuation/dose reduction:
Ventricular hypertrophy (1%)
Tic (1%)
Vomiting (1%)
Psychomotor hyperactivity (1%)
Insomnia (1%)
Rash (1%)
Sources:
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Other AEs: Decreased appetite, Insomnia...
Other AEs:
Decreased appetite (below serious, 29 patients)
Insomnia (below serious, 7 patients)
Weight decreased (below serious, 3 patients)
Irritability (below serious, 6 patients)
Fatigue (below serious, 4 patients)
Nasopharyngitis (below serious, 2 patients)
Sources:
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Nausea...
Other AEs:
Nausea (below serious, 1 patient)
Sources:
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 4 patients)
Nausea (below serious, 1 patient)
Vomiting (below serious, 2 patients)
Sources:
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 2 patients)
Nausea (below serious, 2 patients)
Sources:
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Diarrhea, Dry mouth...
Other AEs:
Diarrhea (below serious, 6 patients)
Dry mouth (below serious, 25 patients)
Fatigue (below serious, 6 patients)
Feeling jittery (below serious, 10 patients)
Irritability (below serious, 8 patients)
Upper respiratory tract infection (below serious, 5 patients)
Heart rate increased (below serious, 4 patients)
Weight decreased (below serious, 8 patients)
Anorexia (below serious, 4 patients)
Decreased appetite (below serious, 26 patients)
Headache (below serious, 20 patients)
Initial insomnia (below serious, 8 patients)
Insomnia (below serious, 10 patients)
Libido decreased (below serious, 4 patients)
Hyperhidrosis (below serious, 5 patients)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Abuse, Dependence...
AEs leading to
discontinuation/dose reduction:
Abuse
Dependence
Cardiovascular disorder (NOS) (grade 3-5)
Stroke (serious)
Myocardial infarction (serious)
Blood pressure increased
Heart rate increased
Psychiatric symptom NOS
Psychotic symptom
Manic symptom
Growth suppression
Vascular disorders
Raynaud's phenomenon
Serotonin syndrome
Sources:
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Decreased appetite, Dry mouth...
Other AEs:
Decreased appetite (below serious, 8 patients)
Dry mouth (below serious, 7 patients)
Insomnia (below serious, 10 patients)
Irritability (below serious, 3 patients)
Diaphoresis (below serious, 2 patients)
Libido decreased (below serious, 2 patients)
Tinnitus (below serious, 2 patients)
Muscle tension (below serious, 4 patients)
Tachycardia (below serious, 3 patients)
Paresthesia (below serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Decreased appetite 0.86%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Insomnia 0.86%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Irritability 1.3%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Hypertension Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Tachycardia Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Tachypnea Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Delirium acute
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Creatine kinase increased mild
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Anxiety 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Dyspnea 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Headache 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Hypertension 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Irritability 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Tachycardia 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Insomnia 2%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Insomnia 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Psychomotor hyperactivity 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Rash 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Tic 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Ventricular hypertrophy 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Vomiting 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Nasopharyngitis below serious, 2 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Decreased appetite below serious, 29 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Weight decreased below serious, 3 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Fatigue below serious, 4 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Irritability below serious, 6 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Insomnia below serious, 7 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Nausea below serious, 1 patient
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Nausea below serious, 1 patient
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Vomiting below serious, 2 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Headache below serious, 4 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Headache below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Nausea below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Feeling jittery below serious, 10 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Insomnia below serious, 10 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Headache below serious, 20 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Dry mouth below serious, 25 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Decreased appetite below serious, 26 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Anorexia below serious, 4 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Heart rate increased below serious, 4 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Libido decreased below serious, 4 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Hyperhidrosis below serious, 5 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Upper respiratory tract infection below serious, 5 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhea below serious, 6 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Fatigue below serious, 6 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Initial insomnia below serious, 8 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Irritability below serious, 8 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Weight decreased below serious, 8 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Abuse Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Blood pressure increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Dependence Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Growth suppression Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Heart rate increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Manic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Psychiatric symptom NOS Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Psychotic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Raynaud's phenomenon Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Serotonin syndrome Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Vascular disorders Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Cardiovascular disorder (NOS) grade 3-5
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Myocardial infarction serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Stroke serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Insomnia below serious, 10 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diaphoresis below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Libido decreased below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Paresthesia below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tinnitus below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Irritability below serious, 3 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tachycardia below serious, 3 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle tension below serious, 4 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry mouth below serious, 7 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Decreased appetite below serious, 8 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely (co-administration study)
Comment: Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism; concomitant use of DEXEDRINE and CYP2D6 inhibitors may increase the exposure of DEXEDRINE;
Page: 4.0
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons.
1999 Jun
Neuronal degeneration in the limbic system of weanling rats exposed to saline, hyperthermia or d-amphetamine.
2000 Dec 8
Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy.
2000 Feb
Effect of the 5-HT3 receptor antagonist ondansetron on amphetamine-induced hyperactivity and stereotypy in rats.
2000 Jul
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.
2001
Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine.
2001
No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy).
2001
The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats.
2001
Anorectic drugs and pulmonary hypertension from the bedside to the bench.
2001 Apr
Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells.
2001 Apr
A nitric oxide-dopamine link pathway in organum vasculosum laminae terminalis of rat brain exerts control over blood pressure.
2001 Apr
Periodic maternal separation of neonatal rats produces region- and gender-specific effects on biogenic amine content in postmortem adult brain.
2001 Apr
Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania.
2001 Feb
Comparison of the effects of infant handling, isolation, and nonhandling on acoustic startle, prepulse inhibition, locomotion, and HPA activity in the adult rat.
2001 Feb
Conditioned activity to amphetamine in transgenic mice expressing an antisense RNA against the glucocorticoid receptor.
2001 Feb
The reverse transport of DA, what physiological significance?
2001 Feb
Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users.
2001 Feb 15
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence.
2001 Feb 16
Selective inhibition of amine oxidases differently potentiate the hypophagic effect of benzylamine in mice.
2001 Feb 9
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
2001 Jan
Environmental novelty differentially affects c-fos mRNA expression induced by amphetamine or cocaine in subregions of the bed nucleus of the stria terminalis and amygdala.
2001 Jan 15
Behavioral activation in rats requires endogenous ascorbate release in striatum.
2001 Jan 15
Neonatal dexamethasone on day 7 in rats causes behavioral alterations reflective of hippocampal, but not cerebellar, deficits.
2001 Jan-Feb
Computer-aided screening for hallucinogenic and stimulant amphetamines with gas chromatography-Fourier transform infrared spectroscopy (GC-FTIR).
2001 Jan-Feb
Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes.
2001 Mar
Adrenergic hyperactivity and metanephrine excess in the nucleus accumbens after prefrontocortical dopamine depletion.
2001 Mar
Acute myocardial infarction associated with amphetamine use.
2001 Mar
Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine.
2001 Mar
Previous exposure to amphetamine enhances the subsequent locomotor response to a D1 dopamine receptor agonist when glutamate reuptake is inhibited.
2001 Mar 1
Dopaminergic role in stimulant-induced wakefulness.
2001 Mar 1
Differential effects of endomorphin-1 and -2 on amphetamine sensitization: neurochemical and behavioral aspects.
2001 Mar 1
Sexual behavior induction of c-Fos in the nucleus accumbens and amphetamine-stimulated locomotor activity are sensitized by previous sexual experience in female Syrian hamsters.
2001 Mar 15
Dissociations between the effects of intra-accumbens administration of amphetamine and exposure to a novel environment on accumbens dopamine and cortical acetylcholine release.
2001 Mar 16
Serotonin transporter localization in the hamster suprachiasmatic nucleus.
2001 Mar 2
Amphetamine-stimulated cortical acetylcholine release: role of the basal forebrain.
2001 Mar 9
Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
2001 May
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans.
2001 May
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene.
2001 May 1
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
2008 Mar
Alopecia following initiation of lisdexamfetamine in a pediatric patient.
2009
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine.
2009
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
2010
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine.
2010 Jun 24
New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children.
2010 May 25
Use of psychostimulants in patients with dementia.
2010 Oct
Patents

Sample Use Guides

Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, DEXEDRINE may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. SPANSULE capsules may be used for once-a-day dosage wherever appropriate.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The action of several concentrations of d-amphetamine on the NADH-tetrazolium reductase histochemical reaction has been studied in several nervous regions of rats. The facts observed have demonstrated that d-amphetamine increases the intensity of the histochemical reaction by its action on NADH-oxido-reductase activity in all nervous regions studied.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:49:59 GMT 2025
Edited
by admin
on Mon Mar 31 17:49:59 GMT 2025
Record UNII
TZ47U051FI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMFETAMINE
INN   WHO-DD  
INN  
Preferred Name English
DEXTROAMPHETAMINE
HSDB   MI   USAN   VANDF  
USAN  
Official Name English
AMPHETAMINE, D-
Common Name English
dexamfetamine [INN]
Common Name English
AMFETAMINE, (S)-
Common Name English
DEXIDRINE
Common Name English
DEXTROAMPHETAMINE [USAN]
Common Name English
NSC-73713
Code English
DEXTROAMPHETAMINE [HSDB]
Common Name English
(S)-1-PHENYL-2-AMINOPROPANE
Systematic Name English
(+)-.ALPHA.-METHYLPHENETHYLAMINE
Systematic Name English
Dexamfetamine [WHO-DD]
Common Name English
DEXAMPHETAMINE
Common Name English
(+)-(S)-AMPHETAMINE
Systematic Name English
BENZENEETHANAMINE, .ALPHA.-METHYL-, (S)-
Systematic Name English
DEXTROAMPHETAMINE [MI]
Common Name English
D-AMPHETAMINE
Common Name English
XELSTRYM
Brand Name English
DEXTROAMPHETAMINE [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QN06BA02
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
CFR 21 CFR 310.502
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
WHO-ATC N06BA02
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
NDF-RT N0000175739
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
NCI_THESAURUS C47795
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
EPA PESTICIDE CODE 600005
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
LIVERTOX 293
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
NDF-RT N0000175729
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
Code System Code Type Description
RXCUI
3288
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID8022907
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
DAILYMED
TZ47U051FI
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
CAS
51-64-9
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
NSC
73713
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
CHEBI
4469
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
INN
1430
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
DRUG CENTRAL
841
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
ChEMBL
CHEMBL612
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
FDA UNII
TZ47U051FI
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
LACTMED
Dextroamphetamine
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
EVMPD
SUB07019MIG
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
SMS_ID
100000088421
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
DRUG BANK
DB01576
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
WIKIPEDIA
DEXTROAMPHETAMINE
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
PUBCHEM
5826
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-112-1
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
MERCK INDEX
m4226
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY Merck Index
IUPHAR
2147
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
MESH
D003913
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
NCI_THESAURUS
C28981
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
HSDB
3055
Created by admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC Adult
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION